<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>accelerated phase &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/accelerated-phase/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 26 Oct 2026 17:55:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>accelerated phase &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Gene Mutations Flag Poor Survival in Advanced Myeloproliferative Neoplasms</title>
		<link>https://bioengineer.org/gene-mutations-flag-poor-survival-in-advanced-myeloproliferative-neoplasms/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 26 Oct 2026 17:55:47 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[accelerated phase]]></category>
		<category><![CDATA[blast phase]]></category>
		<category><![CDATA[EZH2]]></category>
		<category><![CDATA[hypomethylating agents]]></category>
		<category><![CDATA[intensive chemotherapy]]></category>
		<category><![CDATA[karyotype]]></category>
		<category><![CDATA[myeloproliferative neoplasms]]></category>
		<category><![CDATA[ruxolitinib]]></category>
		<category><![CDATA[SF3B1]]></category>
		<category><![CDATA[survival]]></category>
		<category><![CDATA[TP53]]></category>
		<category><![CDATA[Venetoclax]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=454957</guid>

					<description><![CDATA[A retrospective review of 88 patients with advanced Philadelphia chromosome-negative myeloproliferative neoplasms identifies age, white blood cell count, prior myelofibrosis, adverse karyotype, and TP53, EZH2, and SF3B1 mutations as predictors of poorer survival, while venetoclax-based combinations and intensive chemotherapy were associated with longer survival in blast phase.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">454957</post-id>	</item>
	</channel>
</rss>
